Items related to Drug Discovery in Cancer Epigenetics (Translational...
Synopsis
Drug Discovery in Cancer Epigenetics is a practical resource for scientists involved in the discovery, testing, and development of epigenetic cancer drugs. Epigenetic modifications can have significant implications for translational science as biomarkers for diagnosis, prognosis or therapy prediction. Most importantly, epigenetic modifications are reversible and epigenetic players are found mutated in different cancers; therefore, they provide attractive therapeutic targets. There has been great interest in developing and testing epigenetic drugs, which inhibit DNA methyltransferases, histone modifying enzymes or chromatin reader proteins. The first few drugs are already FDA approved and have made their way into clinical settings. This book provides a comprehensive summary of the epigenetic drugs currently available and aims to increase awareness in this area to foster more rapid translation of epigenetic drugs into the clinic.
- Highlights the potential of epigenetic alterations in cancer for drug development
- Covers the tools and methods for epigenetic drug discovery, preclinical and clinical testing, and clinical implications of epigenetic therapy
- Provides important information regarding putative epigenetic targets, epigenetic technologies, networks and consortia for epigenetic drug discovery and routes for translation
"synopsis" may belong to another edition of this title.
About the Authors
Dr. Gerda Egger is an Associate Professor of Epigenetics at the Clinical Institute of Pathology, Medical University of Vienna.
Dr. Paola Barbara Arimondo is the Director of the Unité de Service et de Recherche (USR n°3388) entitled “Epigenetic Targeting of Cancer –ETaC-“ which brings together basic and applied research – a joint laboratory of the Institut de Recherche Pierre Fabre (IRPF) and the CNRS. She is extremely experienced in researching regulatory pharmaceuticals and cancer epigenetics.
"About this title" may belong to another edition of this title.
Buy New
View this item
£ 98.31
£ 3.03 shipping from Italy to United Kingdom
Destination, rates & speedsSearch results for Drug Discovery in Cancer Epigenetics (Translational...
Stock Image
Drug Discovery in Cancer Epigenetics
Print on DemandSeller: Brook Bookstore On Demand, Napoli, NA, Italy
Seller rating 5 out of 5 stars
Condition: new. Questo è un articolo print on demand. Seller Inventory # 8217d68e366f130cf6ec187fa1fb1b28
Quantity: Over 20 available
Stock Image
Drug Discovery in Cancer Epigenetics (Translational Epigenetics Series)
Published by
Academic Press 2016-02-05, 2016
ISBN 10: 0128022086
ISBN 13: 9780128022085
New
Hardcover
Seller: Chiron Media, Wallingford, United Kingdom
Seller rating 4 out of 5 stars
Hardcover. Condition: New. Seller Inventory # 6666-ELS-9780128022085
Quantity: Over 20 available
Stock Image
Drug Discovery in Cancer Epigenetics
Seller: Revaluation Books, Exeter, United Kingdom
Seller rating 5 out of 5 stars
Hardcover. Condition: Brand New. 1st edition. 498 pages. 9.50x8.00x1.00 inches. In Stock. Seller Inventory # __0128022086
Quantity: 2 available
Stock Image
Drug Discovery in Cancer Epigenetics
Published by
Elsevier Science Publishing Co Inc, 2015
ISBN 10: 0128022086
ISBN 13: 9780128022085
New
Hardcover
Seller: THE SAINT BOOKSTORE, Southport, United Kingdom
Seller rating 5 out of 5 stars
Hardback. Condition: New. New copy - Usually dispatched within 4 working days. 1200. Seller Inventory # B9780128022085
Quantity: Over 20 available
Seller Image
Drug Discovery in Cancer Epigenetics
Seller: moluna, Greven, Germany
Seller rating 5 out of 5 stars
Condition: New. Drug Discovery in Cancer Epigenetics is a practical resource for scientists involved in the discovery, testing, and development of epigenetic cancer drugs. Epigenetic modifications can have significant implications for translational science as bio. Seller Inventory # 151151580
Quantity: 1 available
Seller Image
Drug Discovery in Cancer Epigenetics
Published by
Elsevier Science Dez 2015, 2015
ISBN 10: 0128022086
ISBN 13: 9780128022085
New
Hardcover
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
Seller rating 5 out of 5 stars
Buch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Drug Discovery in Cancer Epigenetics is a practical resource for scientists involved in the discovery, testing, and development of epigenetic cancer drugs. Epigenetic modifications can have significant implications for translational science as biomarkers for diagnosis, prognosis or therapy prediction. Most importantly, epigenetic modifications are reversible and epigenetic players are found mutated in different cancers; therefore, they provide attractive therapeutic targets. There has been great interest in developing and testing epigenetic drugs, which inhibit DNA methyltransferases, histone modifying enzymes or chromatin reader proteins. The first few drugs are already FDA approved and have made their way into clinical settings. This book provides a comprehensive summary of the epigenetic drugs currently available and aims to increase awareness in this area to foster more rapid translation of epigenetic drugs into the clinic. 498 pp. Englisch. Seller Inventory # 9780128022085
Quantity: 2 available
Seller Image
Drug Discovery in Cancer Epigenetics
Print on DemandSeller: AHA-BUCH GmbH, Einbeck, Germany
Seller rating 5 out of 5 stars
Buch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Drug Discovery in Cancer Epigenetics is a practical resource for scientists involved in the discovery, testing, and development of epigenetic cancer drugs. Epigenetic modifications can have significant implications for translational science as biomarkers for diagnosis, prognosis or therapy prediction. Most importantly, epigenetic modifications are reversible and epigenetic players are found mutated in different cancers; therefore, they provide attractive therapeutic targets. There has been great interest in developing and testing epigenetic drugs, which inhibit DNA methyltransferases, histone modifying enzymes or chromatin reader proteins. The first few drugs are already FDA approved and have made their way into clinical settings. This book provides a comprehensive summary of the epigenetic drugs currently available and aims to increase awareness in this area to foster more rapid translation of epigenetic drugs into the clinic. Seller Inventory # 9780128022085
Quantity: 2 available